GO:0007259 cell surface receptor signaling pathway via JAK-STAT: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007259 describes the cell surface receptor signaling pathway in which ligand binding induces receptor dimerization, bringing receptor-associated JAKs into close proximity so they phosphorylate and activate each other on tyrosine residues.
• Activated JAKs phosphorylate STAT proteins, which then dissociate from the receptor, translocate to the nucleus, and regulate target gene expression.
• The pathway is central to cytokine signaling, including interleukin-6 (IL-6) family cytokines that signal through gp130/JAK2/STAT3.
• Dysregulated JAK-STAT signaling is implicated in myelofibrosis and other hematologic malignancies, where targeted therapies such as JAK inhibitors are used.
• JAK-STAT signaling also shapes immune cell function, including macrophage apoptosis and polarization, CAR T cell effector functions, and melanoma cell-intrinsic PD-1 expression.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of JAK-STAT pathway components in disease and immunity.
Description
GO:0007259, cell surface receptor signaling pathway via JAK-STAT, is a biological process that converts extracellular cytokine and growth factor signals into changes in gene expression. The pathway begins when a ligand binds a cell surface receptor, causing the receptor to dimerize and bringing receptor-associated Janus kinases (JAKs) into close proximity. The JAKs then phosphorylate and activate each other on tyrosine residues, leading to activation of associated STAT proteins. This architecture allows cells to respond rapidly to interleukin-6 (IL-6) family cytokines and other ligands that use gp130/JAK2/STAT3 signaling. The pathway is essential for normal development, hematopoiesis, and immune regulation, and its dysregulation contributes to inflammatory diseases, cancer, and immune dysfunction. Researchers study GO:0007259 to understand how cytokine signals are transmitted, how specificity is achieved among JAKs and STATs, and how pathway components can be targeted therapeutically. Because the pathway ends with STAT-mediated regulation of target gene expression, it is a prime example of signal transduction coupled directly to transcriptional control.
cell surface receptor signaling pathway via JAK-STAT At A Glance
| GO ID | GO:0007259 |
|---|---|
| GO term | cell surface receptor signaling pathway via JAK-STAT |
| Ontology | biological_process |
| Synonym | JAK-STAT cascade; JAK-STAT signal transduction; receptor signaling pathway via JAK-STAT |
| Major function | Transduces cytokine and growth factor signals from cell surface receptors to the nucleus via JAK-mediated STAT activation |
| Key kinases | JAK1, JAK2, JAK3, TYK2 |
| Key transcription factors | STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6 |
| Representative ligands | IL-6 family cytokines, type I interferons, IL-22 |
| Pathway output | Regulation of target gene expression by STAT proteins |
What Is GO:0007259?
In our own words, GO:0007259 is the cell surface receptor signaling pathway in which ligand binding causes receptor dimerization, bringing receptor-associated JAKs into close proximity. The JAKs phosphorylate and activate each other on tyrosine residues, which leads to activation of associated STAT proteins. The STATs then dissociate from the receptor, translocate to the nucleus, and regulate target gene expression. The pathway is also known as the JAK-STAT cascade or JAK-STAT signal transduction.
Why Is cell surface receptor signaling pathway via JAK-STAT Important in Cell Biology?
GO:0007259 is important because it is one of the principal mechanisms by which extracellular cytokines and growth factors control gene expression. The pathway is required for normal immune responses, hematopoiesis, and tissue homeostasis, and it is frequently dysregulated in disease. For example, IL-6 is a masterplayer in the cytokine network and signals through gp130/JAK2/STAT3. In myelofibrosis, JAK-STAT pathway activation drives disease biology and is the target of approved and investigational therapies. In immune cells, JAK-STAT signaling modulates macrophage apoptosis and polarization, CAR T cell effector functions, and melanoma cell-intrinsic PD-1 expression. Understanding GO:0007259 therefore has direct implications for immunology, oncology, and therapeutic development.
• Controls transcriptional responses to IL-6 family cytokines through gp130/JAK2/STAT3 signaling.
• Regulates immune cell survival, polarization, and effector function, including macrophages and CAR T cells.
• Modulates immune checkpoint molecules such as PD-1 in melanoma cells.
• Is a therapeutic target in myelofibrosis and other hematologic malignancies.
• Mediates signaling by type I interferons and interleukin-22.
• Provides a paradigm for receptor dimerization-driven kinase activation.
• Links extracellular cues directly to STAT-dependent gene expression.
• Is amenable to CRISPR-based genetic dissection of pathway components.
What Happens During cell surface receptor signaling pathway via JAK-STAT?
Ligand binding and receptor dimerization
In simple terms: A cytokine binds its receptor, causing two receptor molecules to pair up.
The pathway is initiated when a ligand binds to a cell surface receptor, causing the receptor to dimerize. This dimerization brings receptor-associated JAKs into close proximity, which is a prerequisite for their activation. For IL-6 family cytokines, ligand binding to the gp130 receptor complex triggers JAK2 activation and downstream STAT3 signaling.
JAK activation by trans-phosphorylation
In simple terms: The paired JAK enzymes activate each other by adding phosphate groups.
Once brought together, the receptor-associated JAKs phosphorylate and activate each other on tyrosine residues. This trans-phosphorylation event is a key step in the pathway and leads to activation of associated STAT proteins. JAK2 is a major kinase in IL-6 family signaling, and its activation is required for downstream STAT3 phosphorylation.
STAT phosphorylation and dissociation from the receptor
In simple terms: The JAKs tag STAT proteins with phosphates, and the STATs then leave the receptor.
Activated JAKs phosphorylate STAT proteins on tyrosine residues, causing the STATs to dissociate from the receptor. This step is essential for transmitting the signal from the membrane to the nucleus. In IL-6 signaling, STAT3 is a principal downstream effector that becomes phosphorylated and activated.
STAT nuclear translocation and target gene regulation
In simple terms: The activated STATs move into the nucleus and turn target genes on or off.
After dissociation from the receptor, activated STATs translocate to the nucleus, where they regulate target gene expression. This final step defines the output of GO:0007259 and links cytokine signals to changes in transcription. STAT3 target genes mediate diverse effects, including muscle wasting during sepsis and immune modulation in tumors.
Pathway modulation in immune and cancer cells
In simple terms: The pathway can be tuned up or down in different cell types, affecting disease outcomes.
JAK-STAT signaling is modulated in context-dependent ways. For example, TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice. Cullin-5 deficiency promotes CAR T cell effector functions potentially via modulation of JAK/STAT signaling. Type I interferon signaling induces melanoma cell-intrinsic PD-1, and its inhibition antagonizes immune checkpoint blockade.
Key Genes Involved in GO:0007259 cell surface receptor signaling pathway via JAK-STAT
The following genes and proteins are core components or context-specific modulators of GO:0007259, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| JAK1 | Janus kinase that phosphorylates STAT proteins | Core kinase in cytokine signaling |
| JAK2 | Janus kinase activated by gp130/IL-6 family cytokines | Key mediator of IL-6/gp130/STAT3 signaling |
| JAK3 | Janus kinase involved in cytokine receptor signaling | Component of JAK-STAT pathway |
| TYK2 | Janus kinase involved in cytokine receptor signaling | Component of JAK-STAT pathway |
| STAT1 | Signal transducer and activator of transcription | Mediates interferon and cytokine responses |
| STAT2 | Signal transducer and activator of transcription | Mediates type I interferon signaling |
| STAT3 | Signal transducer and activator of transcription | Central effector of IL-6/gp130 signaling |
| STAT4 | Signal transducer and activator of transcription | Component of JAK-STAT pathway |
| STAT5A | Signal transducer and activator of transcription | Component of JAK-STAT pathway |
| STAT5B | Signal transducer and activator of transcription | Component of JAK-STAT pathway |
| STAT6 | Signal transducer and activator of transcription | Component of JAK-STAT pathway |
| IL6 | Cytokine ligand that activates JAK-STAT signaling | Masterplayer in cytokine network |
| IL6ST (gp130) | Shared receptor subunit for IL-6 family cytokines | Required for JAK2/STAT3 activation |
| IL22 | Cytokine that signals via JAK-STAT | Regulates tissue responses |
| TREM2 | Modulates macrophage apoptosis and polarization via JAK-STAT | Renal injury model |
| CUL5 | Modulates JAK/STAT signaling in CAR T cells | CAR T cell effector function |
| PDCD1 (PD-1) | Immune checkpoint induced by type I interferon signaling | Melanoma immune checkpoint blockade |
How Is cell surface receptor signaling pathway via JAK-STAT Regulated?
GO:0007259 is regulated at multiple levels. Receptor dimerization and JAK trans-phosphorylation are initiating events that are tightly controlled by ligand availability and receptor expression. In IL-6 family signaling, gp130/JAK2/STAT3 activation is a key regulatory node, and its intensity and duration influence outcomes such as muscle wasting during sepsis. Type I interferon signaling can induce melanoma cell-intrinsic PD-1, and inhibition of this pathway antagonizes immune checkpoint blockade, indicating that JAK-STAT regulation intersects with immune checkpoint control. Cullin-5 deficiency modulates JAK/STAT signaling to promote CAR T cell effector functions, showing that ubiquitin-related proteins can regulate pathway activity. TREM2 deficiency promotes macrophage apoptosis and polarization via the JAK-STAT pathway in renal injury, further illustrating context-dependent regulation.
cell surface receptor signaling pathway via JAK-STAT and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JAK2 | Myelofibrosis and hematologic malignancies | Knockout or point-mutation cell models |
| TREM2 | Renal injury and macrophage apoptosis/polarization | Knockout mouse or macrophage cell model |
| CUL5 | CAR T cell effector function | Knockout CAR T cells |
| PDCD1 (PD-1) | Melanoma immune checkpoint blockade | Knockout or overexpression melanoma cell models |
| IL6 | Sepsis and muscle wasting | Knockout or overexpression cell models |
Myelofibrosis and hematologic malignancies
JAK-STAT pathway activation is central to the biology of myelofibrosis, and targeted therapies including JAK inhibitors are used in its management. Present and ongoing studies continue to refine how pathway inhibition can alter disease course.
Renal injury and macrophage biology
TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice, linking GO:0007259 to inflammatory kidney disease.
Cancer immunotherapy and immune checkpoint regulation
Type I interferon signaling induces melanoma cell-intrinsic PD-1, and its inhibition antagonizes immune checkpoint blockade, demonstrating that JAK-STAT signaling can shape responses to immunotherapy. Cullin-5 deficiency promotes CAR T cell effector functions potentially via modulation of JAK/STAT signaling, highlighting a role in engineered T cell therapy.
Sepsis and muscle wasting
Sepsis induces interleukin 6, gp130/JAK2/STAT3 signaling, and muscle wasting, connecting GO:0007259 to systemic inflammatory conditions and tissue catabolism.
From cell surface receptor signaling pathway via JAK-STAT-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is JAK2 required for IL-6-induced STAT3 activation? | JAK2 knockout cell line |
| Does a specific STAT3 tyrosine mutation affect target gene expression? | STAT3 point-mutation knock-in |
| Can STAT3 activation be monitored in live cells? | STAT3 tagged knock-in |
| Does CUL5 loss enhance CAR T cell effector function via JAK/STAT? | CUL5 knockout CAR T cells |
| Does TREM2 deficiency alter macrophage polarization via JAK-STAT? | TREM2 knockout macrophages |
| Does type I interferon-induced PD-1 depend on JAK-STAT signaling? | PDCD1 overexpression or knockout melanoma cells |
How to Study the cell surface receptor signaling pathway via JAK-STAT Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Changes in STAT target gene expression | Transcriptional output of JAK-STAT signaling |
| Western blot | Phosphorylated JAK and STAT protein levels | Pathway activation after cytokine stimulation |
| Phospho-flow cytometry | Single-cell phosphorylation of STAT proteins | Immune cell signaling analysis |
| CRISPR knockout | Loss-of-function effects of pathway genes | Causal testing of JAK-STAT components |
| CRISPR point mutation | Effect of specific amino acid changes | Dissecting STAT phosphorylation sites |
| CRISPR knock-in | Tagged or reporter allele expression | Monitoring pathway activity in live cells |
| Overexpression | Gain-of-function effects of pathway genes | Testing oncogenic or immune roles |
| Macrophage polarization assay | M1/M2 marker expression | Renal injury and inflammation models |
Transcriptional readouts of STAT activity
RNA-seq can measure changes in STAT target gene expression following cytokine stimulation or genetic perturbation. This approach is useful for defining the transcriptional output of GO:0007259 in contexts such as IL-6/gp130/STAT3 signaling.
Phospho-protein analysis
Western blotting or phospho-flow cytometry can detect phosphorylated JAKs and STATs, providing direct evidence of pathway activation. These methods are standard for assessing JAK2 and STAT3 phosphorylation in IL-6 family signaling.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of pathway components. Examples include CUL5 knockout in CAR T cells, TREM2 knockout in macrophages, and PDCD1 modulation in melanoma cells.
Functional immune assays
Macrophage polarization assays, CAR T cell effector function assays, and immune checkpoint blockade models can link JAK-STAT pathway changes to immune phenotypes.
How CRISPR Can Be Used to Study GO:0007259 cell surface receptor signaling pathway via JAK-STAT
Knockout
CRISPR knockout of JAKs, STATs, or modulators such as CUL5 and TREM2 can reveal their requirement for GO:0007259. For example, CUL5 deficiency promotes CAR T cell effector functions potentially via modulation of JAK/STAT signaling, and TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway.
Point Mutation
CRISPR point mutation can be used to test the function of specific tyrosine residues in JAKs or STATs that are phosphorylated during pathway activation. This approach helps define which phosphorylation events are required for STAT activation and target gene regulation.
Knock-in
Knock-in of tags or reporters into JAK or STAT loci allows monitoring of pathway activation, localization, and dynamics. Such models can be used to track STAT nuclear translocation and target gene regulation in real time.
Overexpression
Overexpression of ligands, receptors, or STATs can amplify pathway output and model disease states. For example, type I interferon signaling induces melanoma cell-intrinsic PD-1, and its inhibition antagonizes immune checkpoint blockade, a context where overexpression or knockout of PDCD1 can be informative.
How EDITGENE Supports cell surface receptor signaling pathway via JAK-STAT Research
Researchers studying cell surface receptor signaling pathway via JAK-STAT-related genes often need to determine whether a candidate gene is causally involved in pathway activation, immune regulation, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations of JAK-STAT components, from knockout to knock-in and overexpression, supported by library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for cell surface receptor signaling pathway via JAK-STAT research.
Frequently Asked Questions About cell surface receptor signaling pathway via JAK-STAT
What is GO:0007259?
GO:0007259 is the Gene Ontology term for cell surface receptor signaling pathway via JAK-STAT, in which ligand binding causes receptor dimerization, JAK activation, STAT phosphorylation, and STAT-mediated regulation of target gene expression.
What is the JAK-STAT signaling pathway?
The JAK-STAT pathway is a cell surface receptor signaling pathway that transmits cytokine signals to the nucleus through JAK kinases and STAT transcription factors.
What genes are involved in cell surface receptor signaling pathway via JAK-STAT?
Key genes include JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, IL6, IL6ST (gp130), IL22, TREM2, CUL5, and PDCD1.
How does IL-6 activate JAK-STAT signaling?
IL-6 family cytokines bind gp130 receptor complexes, activating JAK2 and downstream STAT3 phosphorylation, which leads to target gene expression.
What diseases are linked to JAK-STAT signaling?
JAK-STAT signaling is linked to myelofibrosis and hematologic malignancies, renal injury, sepsis-associated muscle wasting, and melanoma immune checkpoint regulation.
What is the role of STAT3 in the JAK-STAT pathway?
STAT3 is a key transcription factor activated downstream of JAK2 in IL-6 family signaling, and it regulates genes involved in inflammation, muscle wasting, and immune responses.
How can CRISPR be used to study JAK-STAT signaling?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the function of JAKs, STATs, and modulators such as CUL5 and TREM2 in pathway activity and disease models.
What is the difference between JAK-STAT and other signaling pathways?
JAK-STAT is distinct because receptor dimerization directly activates receptor-associated JAK kinases, which phosphorylate STAT transcription factors that then translocate to the nucleus to regulate gene expression.
Which cytokines signal through the JAK-STAT pathway?
IL-6 family cytokines, type I interferons, and interleukin-22 are examples of cytokines that signal through JAK-STAT.
Why is JAK-STAT signaling important in cancer?
JAK-STAT signaling can drive hematologic malignancies such as myelofibrosis and modulate immune checkpoint molecules such as PD-1 in melanoma, making it a therapeutic target.
Conclusion
GO:0007259, cell surface receptor signaling pathway via JAK-STAT, is a fundamental biological process that converts cytokine and growth factor signals into transcriptional programs. Its core mechanism, from receptor dimerization and JAK activation to STAT nuclear translocation, is well defined and supported by extensive literature. Dysregulation of this pathway contributes to myelofibrosis, renal injury, sepsis-associated muscle wasting, and immune checkpoint regulation in melanoma. CRISPR-based cell models, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to dissect JAK-STAT components and their roles in disease. EDITGENE offers these services to accelerate research on this pathway.
References
- 1. Cui Y et al.. 2024. TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice.. Cell Death Dis 15(6):401 PMID: 38849370
- 2. Uciechowski P et al.. 2020. Interleukin-6: A Masterplayer in the Cytokine Network.. Oncology 98(3):131-137 PMID: 31958792
- 3. Loscocco GG et al.. 2025. Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.. Am J Hematol 100 Suppl 4(Suppl 4):30-50 PMID: 40062529
- 4. Adachi Y et al.. 2024. Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway.. Nat Commun 15(1):10376 PMID: 39658572
- 5. Zanders L et al.. 2022. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.. J Cachexia Sarcopenia Muscle 13(1):713-727 PMID: 34821076
- 6. Heinrich PC et al.. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation.. Biochem J 374(Pt 1):1-20 PMID: 12773095
- 7. Holzgruber J et al.. 2024. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade.. Nat Commun 15(1):7165 PMID: 39187481
- 8. Wolk K et al.. 2010. Biology of interleukin-22.. Semin Immunopathol 32(1):17-31 PMID: 20127093
